Is FDA's revolving door open too wide?

. 2018 Jul 6;361(6397):21.

doi: 10.1126/science.361.6397.21.

Charles Piller. Science. 2018.

. 2018 Jul 6;361(6397):21.

doi: 10.1126/science.361.6397.21.

No abstract available

Similar articles

Revisiting financial conflicts of interest in FDA advisory committees.
Pham-Kanter G. Pham-Kanter G. Milbank Q. 2014 Sep;92(3):446-70. doi: 10.1111/1468-0009.12073. Milbank Q. 2014. PMID: 25199895 Free PMC article.
Financial conflicts of interest are related to voting patterns at FDA Advisory Committee meetings.
Lurie P. Lurie P. MedGenMed. 2006 Oct 30;8(4):22. MedGenMed. 2006. PMID: 17415305 Free PMC article. No abstract available.
Hidden conflicts?
Piller C. Piller C. Science. 2018 Jul 6;361(6397):16-20. doi: 10.1126/science.361.6397.16. Science. 2018. PMID: 29976808 No abstract available.
[FDA's new drug approval system].
Ishii A. Ishii A. Gan To Kagaku Ryoho. 1995 Aug;22(9):1146-51. Gan To Kagaku Ryoho. 1995. PMID: 7661565 Review. Japanese. No abstract available.
Overview of the 2014 Food and Drug Administration Cardiovascular and Renal Drugs Advisory Committee meeting regarding cangrelor.
Lhermusier T, Baker NC, Waksman R. Lhermusier T, et al. Am J Cardiol. 2015 Apr 15;115(8):1154-61. doi: 10.1016/j.amjcard.2015.01.551. Epub 2015 Feb 3. Am J Cardiol. 2015. PMID: 25728646 Review.

Talc, Asbestos, and Epidemiology: Corporate Influence and Scientific Incognizance.
Tran TH, Steffen JE, Clancy KM, Bird T, Egilman DS. Tran TH, et al. Epidemiology. 2019 Nov;30(6):783-788. doi: 10.1097/EDE.0000000000001091. Epidemiology. 2019. PMID: 31469695 Free PMC article. No abstract available.